Trial Profile
Multicenter, Open, Randomized Study With Active Control to Evaluate the Early Bactericidal Activity, Safety and Pharmacokinetics of the Drug PBTZ169 When Used in Patients With First-diagnosed Tuberculosis of the Respiratory System With Bacterial Excretion and Saved Bacterial Susceptibility to Isoniazid and Rifampicin
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2020
Price :
$35
*
At a glance
- Drugs Macozinone (Primary) ; Isoniazid
- Indications Tuberculosis
- Focus Therapeutic Use
- Sponsors NEARMEDIC
- 15 Mar 2018 Status changed from suspended to discontinued due to slow recruitment.
- 10 Nov 2017 New trial record